Novo Nordisk Shares Drop as Investors Disappointed by Vague Turnaround Strategy
Novo Nordisk shares fell sharply in early trading after the company outlined a long-term strategy that failed to impress investors. The Danish drugmaker announced plans for more than five blockbuster drugs and over $23 billion in new sales by 2035, but these broad targets were seen as insufficiently detailed. Investors had hoped for clearer guidance on how Novo will replace revenue from its obesity treatments Wegovy and Ozempic once their patents expire around the start of the next decade. The company's CEO, Mike Doustdar, emphasized diversification efforts targeting broader consumer segments through pipeline drugs and potential M&A activity. However, these plans were viewed as vague during Novo’s capital markets day event. While shares initially dropped significantly, they partially recovered by midday trading on September 21. The market reaction highlights investor concerns about the company's ability to maintain its competitive edge in a rapidly evolving obesity drug landscape now dominated by Eli Lilly.
Topics: blockbuster drugs capital markets day investor sentiment obesity drugs pharmaceuticals